[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Abbott Diabetes Care\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100649706","evaluating-the-occurrence-of-dka-in-people-with-type-i-diabetes-100649706",false,"NCT07739342","Evaluating the Occurrence of DKA in People With Type I Diabetes","Evaluating the Occurrence of DKA in People With Type 1 Diabetes","Inclusion Criteria:\n\n1. Aged at least 2 years old at the time of study enrollment.\n2. Diagnosis of type 1 diabetes with at least 12 months of diabetes medical history.\n3. In the investigator's opinion, the participant is willing to wear the sensor, follow study specific instructions, and perform all study tasks.\n4. Willing and able to provide written signed and dated informed consent (adults) or participant's parent\u002Flegal guardian must be willing and able to provide written signed and dated informed consent along with assent form completed by the participant for those mature enough to make their own decisions per investigator assessment (those less than 16 years of age).\n\nExclusion Criteria:\n\n1. In the investigator's opinion, the participant has a known (or suspected) allergy to medical grade adhesives at enrollment that would interfere with participant completing study required activities.\n2. In the investigator's opinion, the participant has concomitant medical condition(s) which could interfere with the study or present a risk to the safety or welfare of the participant or study staff.\n3. Participant is currently in another clinical study which may affect glucose or ketone management (or does so during the study).\n4. Participant is unsuitable for participation due to any other cause as determined by the investigator.\n5. Participant has implanted medical devices such as pacemakers or requires dialysis or is critically ill.","ALL","2 Years",{"count":19,"type":20},1200,"ESTIMATED","OBSERVATIONAL","This study will evaluate the occurrences of Diabetes-related Ketoacidosis (DKA) in adult and pediatric individuals living with Type I diabetes while managing diabetes with Abbott's Continuous Monitoring Systems.",[24],"Type 1 Diabetes","NOT_YET_RECRUITING","2026-07-28",{"date":28,"type":29},"2026-07-31","ACTUAL",{"date":31,"type":20},"2026-09",{"date":33,"type":20},"2027-12",{"name":35,"class":36},"Abbott Diabetes Care","INDUSTRY",7,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100586939","glycemic-metrics-and-patterns-in-people-with-and-without-prediabetes-100586939","NCT06921902","Glycemic Metrics and Patterns in People With and Without Prediabetes","Observation and Identification of Glycemic Metrics and Patterns in People With and Without Prediabetes (PREMAP)","PREMAP","Inclusion Criteria:\n\n* Subject must be at least 18 years of age.\n* Subject must be willing and able to provide written signed and dated informed consent.\n\nExclusion Criteria:\n\n* Subject has a diagnosis of type 1 diabetes, type 2 diabetes, or gestational diabetes.\n* Subject is known to be currently practicing a low-carbohydrate or ketogenic diet at the time of enrollment.\n* Subject is known to be pregnant at the time of enrollment.\n* Subject has known allergy to medical grade adhesive, isopropyl alcohol and\u002For ethyl alcohol used to disinfect skin.\n* Subject is currently on any form of treatment indicated for the treatment of diabetes.\n* Subject is currently on any form of medication indicated for weight loss.",true,"18 Years",{"count":49,"type":20},2000,"The FreeStyle Libre 3 Continuous Glucose Monitoring (FSL3) System is used to characterize the glycemic profiles of people with and without a prediabetes diagnosis.",[52],"Pre Diabetes","RECRUITING","2026-04-06",{"date":56,"type":29},"2026-04-09",{"date":58,"type":29},"2025-02-28",{"date":60,"type":20},"2026-12",{"name":35,"class":36},1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100567495","prolongation-of-glp-1-adherence-when-using-continuous-glucose-monitoring-100567495","NCT06668935","Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring","Inclusion Criteria:\n\n1. Subject must be at least 18 years of age.\n2. Subject must be able to read and understand English.\n3. Subject must have a type 2 diabetes diagnosis.\n4. In the investigator's opinion, subject must meet the criteria for beginning use of GLP-1 or GIP\u002FGLP-1 medications for management of their diabetes.\n5. Subject is beginning use of GLP-1 \u002F GIP\u002FGLP-1 medication for management of their diabetes.\n6. Subject must be willing to allow venous samples to be obtained to test HbA1c.\n7. Subject must be willing to either continue using their existing standard of care device or must be willing to use the FreeStyle Libre 3 Continuous Glucose Monitoring System to manage their diabetes throughout the duration of the study.\n8. In the investigator's opinion, the subject must be able to follow the instructions provided to him\u002Fher by the study site and perform all study tasks as specified by the protocol.\n9. Subject must be available to participate in all study visits.\n10. Subject must be willing and able to provide written signed and dated informed consent.\n\n    Exclusion Criteria:\n11. Subject is a member of the Study Staff.\n12. Subject has a diagnosis of type 1 or gestational diabetes.\n13. Subject is currently using or has previously used GLP-1 or GIP\u002FGLP-1 drugs for any reason.\n14. Subject is currently using a Continuous Glucose Monitor (CGM) as their standard of care device to manage their diabetes.\n15. Subject has known allergy to medical grade adhesive, isopropyl alcohol and\u002For ethyl alcohol used to disinfect skin.\n16. Subject is taking any type of rapid-acting insulin, including Neutral Protamine Hagedorn (NPH) and premix insulin.\n17. Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff.\n18. Subject currently is participating in another clinical trial.\n19. Subject is unsuitable for participation due to any other cause as determined by the Investigator",{"count":70,"type":20},800,"This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1\u002FGIP) agonists.",[73],"Diabetes Mellitus","2025-01-14",{"date":76,"type":29},"2025-01-15",{"date":78,"type":29},"2024-10-24",{"date":80,"type":20},"2027-01",{"name":35,"class":36},2,""]